Optimizing the Total Cost of Ownership for APIs

RomanR - stock.adobe.com

The production of safe and effective medicines requires access to reliable manufacturers of APIs. However, increasing pressure to reduce market prices of drugs has created deeper challenges for API sourcing organizations, often leading them to consider lower quality and less reliable suppliers. This is a short-sighted approach. Particularly as global quality standards become more harmonized, there are now higher expectations across the globe. And with COVID-19, reliability has also become a top-of-mind topic for manufacturers and healthcare systems.

The best approach to overcoming these challenges is finding a balance in the total cost of manufacturing and selling medicines, also referred to as total cost of ownership, with the right quality API at the right (not cheapest) price.

Read this article in Pharmaceutical Technology’s October 2023 Trends in Formulation eBook.

About the authors

Andrew Badrot, CEO, C² Pharma

Article details

Pharmaceutical Technology
eBook: Trends in Formulation 2023
October 2023
Pages: 26–30

Citation

When referring to this article, please cite it as Badrot, A. Optimizing the Total Cost of Ownership for APIs. Pharmaceutical Technology’s Trends in Formulation eBook (October 2023).